Cloudbreak Pharma (02592.HK) is a global clinical-stage biotechnology company focused on developing ophthalmic drugs for the treatment of chronic eye diseases. The company was founded in September 2015 in Irvine, California, USA. Its team possesses diversified expertise and extensive experience in ophthalmic drug development, with the mission of helping people better enjoy life by treating various eye conditions that impair vision and quality of life. On July 3, 2025, Cloudbreak Pharma was listed on the Hong Kong Stock Exchange. Efung Capital invested in the company twice, in August and September 2022.